Status and phase
Conditions
Treatments
About
This study will evaluate the efficacy, safety, and pharmacokinetics of the PDS with Ranibizumab in participants with DME when treated every 24 weeks (Q24W) compared with intravitreal ranibizumab 0.5 mg every 4 weeks (Q4W).
The substudy will evaluate the safety of re-implanting the updated PDS with ranibizumab and the refill-exchange procedures following re-implantation in participants with DME who were previously enrolled in the main Study, GR40550. Up to 100 participants from the main study will be enrolled and followed for a maximum of 72 weeks post-re-implantation in the substudy.
Enrollment
Sex
Ages
Volunteers
Inclusion criteria
Study eye
Exclusion criteria
Substudy:
Inclusion Criteria:
Exclusion Criteria (Cohort 1 Only):
Ocular Exclusion Criteria for Study Eye:
Primary purpose
Allocation
Interventional model
Masking
634 participants in 5 patient groups
Loading...
Data sourced from clinicaltrials.gov
Clinical trials
Research sites
Resources
Legal